Nanologica Ab · OMXSTO:NICA
Nanologica Ab — Q4 2024 Earnings Presentation
26 slides from Nanologica Ab's earnings presentation, Feb 14, 2025
Slide 1: Year-End Report 2024
YEAR-END REPORT 2024 N A N O LO G I C A A B ( PU B L )
Slide 2: Financial Summary
FINANCIAL SUMMARY • Net sales for the fourth quarter amounted to SEK 6,715 thousand (75) and for the full year to SEK 14,538 thousand (1,443) • Operating loss for the quarter amounted to SEK -11,890 thousand (-35,638) and for the full year to SEK -59,255 thousand (-69,963). For the full year, operat
Slide 3: Sales Record for Chromatography Products
SALES RECORD FOR CHROMATOGRAPHY PRODUCTS In 2024, we reached our highest sales of chromatography products ever with net sales of SEK 14.5 million, of which SEK 6.7 million in the fourth quarter. Sales of our silica media NLAB Saga® were able to start during the summer after we finalized and approved
Slide 4: This is Nanologica
THIS IS NANOLOGICA Better and cheaper medicine to a larger number of patients Nanologica's products are used to purify pharmaceuticals during production through a technique called preparative chromatography. Our main product NLAB Saga®, which is a silica-based purification media for preparative chro
Slide 5: Five Reasons to Invest in Nanologica
FIVE REASONS TO INVEST IN NANOLOGICA By developing chromatography products that enable pharmaceutical manufacturers to streamline their production and lower their production costs, Nanologica not only strives to create value for its shareholders, but also to contribute to more patients having access
Slide 6: Summary of the Fourth Quarter; Operating Income and Result
SUMMARY OF THE FOURTH QUARTER which is an important parameter for gaining During and after the quarter, several customer customers' confidence in the company as a long- visits were made in China, and dialogues are term supplier. ongoing with several customers. Additional orders have been received fr
Slide 7: Investments, Liquidity and Financial Position; Rights Issue
to negative earnings. As of December 31, 2024, The group's reported equity amounted to SEK the group had a tax loss deduction of an amount 74,112 thousand on the balance sheet date, of SEK 402,089 thousand and the parent company compared to SEK -1,898 thousand at the beginning a tax loss deduction o
Slide 8: Fluctuations in Revenue Generation; Employees and Organization
FLUCTUATIONS IN REVENUE and the registered share capital to SEK 8,835,723.4. The share's quota value was SEK 0.1 GENERATION per share. The business generates revenue through the sale of products for preparative and analytical The Extraordinary General Meeting on 23 chromatography, as well as the pro
Slide 9: Financial Calendar, Annual General Meeting, Future Prospects
company during the period 1 August 2026 to 30 statements. Internal and external factors can November 2026 at a subscription price of SEK 30 affect Nanologica's results. per share. In the option program, 180,000 of the total 245,000 options have been subscribed. As the large-scale silica production f
Slide 10: Auditors' Review, Assurance, Risks
level of uncertainty surrounding the impact of the sales mainly in US dollars. Nanologica has not geopolitical situation on the global economy and currently hedged any exchange rates. supply chain may have an impact in the longer term. Climate change poses a major risk to humanity from a global pers
Slide 11: Financial Reports and Notes
FINANCIAL REPORTS AND NOTES
Slide 12: Consolidated Income Statement
CONSOLIDATED INCOME STATEMENT 2024 2023 2024 2023 Amounts in TSEK Oct - Dec Oct - Dec Jan - Dec Jan - Dec Net sales 6 715 75 14 538 1 443 Change in inventories, finished goods 5 530 1 457 18 163 2 080 Capitalized work for own use 0 866 0 3 229 Other operating income 405 228 633 494 Operating expense
Slide 13: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET 2024 2023 Amounts in TSEK Dec 31 Dec 31 ASSETS Fixed assets Intangible fixed assets Capitalized expenditure for research and development and similar 15 234 21 809 Concessions, patents, licenses, trademarks and similar rights 0 1 332 Tangible fixed assets 3 187 3 749 Right-
Slide 14: Consolidated Statement of Changes in Equity
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY 2024 2023 2024 2023 Amounts in TSEK Oct - Dec Oct - Dec Jan - Dec Jan - Dec Total equity at the beginning of the period -8 837 34 840 -1 898 73 158 Profit/loss for the period -14 033 -36 839 -65 629 -75 157 Other comprehensive income 0 0 0 0 Total comprehe
Slide 15: Consolidated Cash Flow Statement
CONSOLIDATED CASH FLOW STATEMENT 2024 2023 2024 2023 Amounts in TSEK Oct - Dec Oct - Dec Jan - Dec Jan - Dec Operating activities Operating profit/loss -11 890 -35 639 -59 255 -69 963 Adjustment for items not affecting cash flow 3 654 8 342 15 359 18 959 Write-down of onerous contract 0 9 785 9 005
Slide 16: Notes
NOTES NOTE 1 GENERAL INFORMATION This report covers the Swedish parent company Nanologica AB (publ), corporate registration number 556664- 5023, and its subsidiaries. The parent company is a limited liability company with its registered office in Stockholm, Sweden. The address of the main office is
Slide 17: Composition of Net Sales by Segment, Region and Customer
Composition of net sales, per segment and region 2024 2023 2024 2023 (TSEK) Oct - Dec Oct - Dec Jan - Dec Jan - Dec Chromatography 6 715 75 14 538 1 443 China* 5 948 58 8 426 654 India 740 17 5 916 188 Rest of the World 27 0 175 601 Business development 0 0 0 0 Rest of the World 0 0 0 0 Total 6 715
Slide 18: Notes on Financial Assets and Liabilities
NOTE 6 INFORMTATION ON FINANCIAL ASSETS AND LIABILITIES For assets and liabilities that are reported at amortized cost, the company assesses that the carrying value of its receivables and liabilities corresponds to fair value. This assessment is based, inter alia, on the discount effect, which is co
Slide 19: Definition of Key Figures
NOTE 10 DEFINITION OF KEY FIGURES The company presents certain financial measures that are not defined under IFRS. These alternative performance measures are used in internal reporting and as part of management's follow-up of the group’s results and financial position. The company believes that thes
Slide 20: Group Quarterly Data
2024 2023 Dec 31 Dec 31 A. Equity according to the balance sheet (TSEK) 74 112 -1 898 B. Total assets according to balance sheet (TSEK) 143 099 77 429 "A/B" = Equity/assets ratio (%) 52 -2 A. Equity according to the balance sheet (TSEK) 74 112 -1 898 B. Number of shares before and after dilution* 88
Slide 21: Income Statement for the Parent Company
INCOME STATEMENT FOR THE PARENT COMPANY 2024 2023 2024 2023 Amounts in TSEK Oct - Dec Oct - Dec Jan - Dec Jan - Dec Net sales 6 715 75 14 538 1 443 Change in inventories, finished goods 5 530 1 457 18 163 2 080 Capitalized work for own use 0 866 0 3 229 Other operating income 405 228 633 494 Operati
Slide 22: Balance Sheet for the Parent Company
BALANCE SHEET FOR THE PARENT COMPANY 2024 2023 Amounts in TSEK Dec 31 31 Dec ASSETS Fixed assets Intangible assets Capitalized expenditure for research and development and similar 16 642 27 391 Concessions, patents, licenses, trademarks and similar rights 0 1 332 Total intangible assets 16 642 28 72
Slide 23: Balance Sheet for the Parent Company
BALANCE SHEET FOR THE PARENT COMPANY 2024 2023 Amounts in TSEK Dec 31 31 Dec EQUITY AND LIABILITIES Equity Share capital 8 836 14 821 Fund for development expenditure 281 748 Total restricted equity 9 117 15 569 Non-restricted equity Share premium reserve 442 173 308 295 Profit/loss brought forward
Slide 24: Statement of Changes in Equity for the Parent Company
STATEMENT OF CHANGES IN EQUITY FOR THE PARENT COMPANY 2024 2023 2024 2023 Amounts in TSEK Oct - Dec Oct - Dec Jan - Dec Jan - Dec Total equity at the beginning of the period -14 926 29 990 -6 940 68 840 Total comprehensive income for the period -14 126 -37 030 -66 008 -75 880 Off set loans through r
Slide 25: Cash Flow Statement for the Parent Company
CASH FLOW STATEMENT FOR THE PARENT COMPANY 2024 2023 2024 2023 Amounts in TSEK Oct - Dec Oct - Dec Jan - Dec Jan - Dec Operating activities Operating profit/loss -12 022 -35 800 -59 768 -70 599 Adjustment for items not affecting cash flow 2 861 7 751 13 372 16 594 Write-down of onerous contract 0 9
Slide 26: Nanologica AB (publ) contact details
Nanologica AB (publ) Forskargatan 20 G SE-151 36 Södertälje, Sweden Ph: +46-8-410 749 49 www.nanologica.com